drugset
drugset / Trial / NCT00207012

MAD Refractory: Solid Tumor QD w/o Break

NCT00207012 ↗

Phase 1 Completed 45 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.

Timeline

Start
2004-05
Primary completion
2006-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AC480 Small molecule — —

Indications

No indication recorded.